No abstract

No abstract

No abstract

response predictive biomarker. However, increased OS has been shown in patients with PBRM-1 LOF mutations and pancreatic metastasis versus without ( HR .34, p[.007). Additionally, PBRM-1 LOF mutations have been associated with less immunogenic, more angiogenic tumor microenvironments, which may portend poorer prognosis. Conflicting or inconclusive evidence exists regarding whether mutated alleles in ERV, mTOR, or VHL are prognostic for OS or PFS. Finally, SETD2 mutations may be associated with metastatic spread to bone.CONCLUSIONS: Overall, we found the strongest consensus for gene mutations in BAP1, CDKN2A, CIMP/FH, and TERT as biomarkers prognostic for OS or PFS, while the prognostic value of PBRM-1, ERV, mTOR, and VHL mutations has yet to be fully elucidated.

respectively). On a yearly report basis, no significant differences were underlined at 3 and 4 years after surgery.CONCLUSIONS: En-bloc plasma-button tumor resection provided the advantages of superior surgical safety, decreased perioperative morbidity and faster recovery when compared to standard TURBT. While preserving the ability of achieving an accurate pathological staging, the en-block therapeutic approach was characterized by an improved oncologic outcome based on the reduced heterotopic NMIBT recurrences up to 2 years, while differences between techniques lost statistical significance at 3 and 4 years.